Roche's European in vitro device business to be folded into Boehringer Mannheim's under integration plan.
This article was originally published in The Gray Sheet
Executive SummaryROCHE EUROPEAN DIAGNOSTICS UNITS WOULD BE FOLDED INTO BOEHRINGER FACILITIES under Roche's integration plan for Boehringer Mannheim. The proposal, which would eliminate 4,000-5,000 of the combined companies' 74,000 employees, calls for Boehringer to take over the functions of Roche's Kaiseraugst, Switzerland and Grenzach, Germany in vitro diagnostics operations. Roche announced a definitive agreement to purchase Boehringer Mannheim parent Corange on May 26 ("The Gray Sheet" June 2, p. 3); the deal is expected to close by the end of the year.
You may also be interested in...
As the coronavirus continues to spread, one of the big four global vaccines companies has committed itself to the fight.
Sweden’s mid-sized pharmaceutical company, Swedish Orphan Biovitrum, has expanded into hematology and strengthened its immunology business, growing its top and bottom lines in 2019.